OBJECTIVES: Acute kidney injury (AKI) is a common postoperative complication after lung transplantation. The aim of the present study was to evaluate the incidence of AKI in lung transplant patients and its effect on patients and graft outcome in relation to degree of severity.
INTRODUCTION
Lung transplantation (LTX) is a viable therapeutic option for patients with end-stage pulmonary disease that cannot be treated by other medical or surgical procedures [1] . Acute kidney injury (AKI) is a common postoperative complication after LTX [2] : an incidence of up to 65% has been reported [3] . It is mainly due to prerenal causes, such as arterial hypotension and low cardiac output. Pulmonary hypertension, extracorporeal circulation and severe bleeding are considered major risk factors for postoperative AKI. Other factors that have been associated with AKI are low baseline glomerular filtration rate, pulmonary diagnosis other than chronic obstructive pulmonary disease, mechanical ventilation (MV) >1 day, postoperative supratherapeutic whole-blood tacrolimus trough concentrations and the use of > _3 other nephrotoxic drugs [4, 5] .
The rate of recovery from AKI is generally low and has been shown to affect survival after LTX [5] . In 2012, Wehbe et al. [3] showed worse survival in patients with AKI, reporting a 1-year survival rate of 91%, 82% and 66% in patients with no AKI, AKI stage 1 and AKI stages 2-3, respectively. A retrospective analysis based on the United Network for Organ Sharing database reported that patients undergoing LTX who required renal replacement therapy (RRT; 5.51% of 12 108 patients) had a decreased survival rate at 30 days (96.7% vs 76.0%; P < 0.001), 1 year (85.5% vs 35.8%; P < 0.001) and 5 years (56.4% vs 20.0%, P < 0.001) and confirmed preoperative kidney function with a glomerular filtration rate <60 ml/min as an important predictor of RRT [6] .
Data from the International Society for Heart and Lung Transplantation shows that renal dysfunction is even more common than diabetes and bronchiolitis obliterans syndrome after LTX (22.9% within 1 year of transplant, 53.9% and 72.0% at 5 years and 10 years) and is significantly correlated with death [7] . Together with immunosuppressive therapy, postoperative AKI is significantly associated with the development of long-term chronic kidney dysfunction [3] [4] [5] .
The aim of the present study was to evaluate the incidence of AKI after LTX at a single institution and its effect on patients and graft outcome in relation to the degree of severity and the need for dialysis. Pre-and postoperative risk factors associated with the onset of AKI were also investigated.
METHODS

Patients
Pre-and postoperative data were collected retrospectively from 135 patients (age 51.2 ± 12.2 years, 84 male) who consecutively underwent LTX from July 2001 to December 2016 at the Siena Lung Transplant Center, Italy. All patients gave their informed consent to participate in the present study, and the University Hospital of Siena institutional review board approved this project.
Immunosuppressive protocol
All patients received corticosteroid therapy consisting of intravenous methylprednisolone 125 mg before graft reperfusion followed by 375 mg on day 0 and tapering from 1 mg/kg on day 1. Induction therapy was introduced in our protocol in 2009; however, since then not all patients have received it, depending on the decision of the surgeon. Most patients (n = 50) were treated with basiliximab (20 mg on day 0 and day 4); only a few (n = 5) received rabbit antithymocyte globulin (1.5 mg/kg/day for 3-5 days). Calcineurin inhibitors were introduced on days 3-5 using either tacrolimus (trough level 10-15 ng/ml before introduction of basiliximab, 8-10 ng/ml thereafter) or cyclosporine (trough level 250-300 ng/ml before introduction of basiliximab, 200-250 ng/ml thereafter). Cyclosporine was used predominantly until 2007; tacrolimus was used thereafter. Azathioprine 100 mg/day or mycophenolate mofetil 1 g/day was introduced in most patients from day 7 to day 10. In 2007, mycophenolate mofetil replaced azathioprine in the baseline regimen for all patients.
Renal function evaluation
Our protocol included daily assessment of renal function for the first 15 days postoperatively, followed by evaluation based on clinical condition. AKI was defined according to Kidney Disease: Improving Global Outcomes criteria [8] : a serum creatinine increase of > _0.3 mg/dl within 48 h, or > _1.5 times basal values, which is known or presumed to have occurred within the prior 7 days, or urine output <0.5 ml/kg/h for 6 consecutive hours. Postoperative AKI was confirmed when renal failure occurred within 7-14 days after the transplant.
The severity of AKI was stratified into 3 stages: stage 1 was a serum creatinine increase of > _0.3 mg/dl, or 1.5-1.9 times basal values, or urine output <0.5 ml/kg/h for 6-12 consecutive hours; stage 2 was a serum creatinine increase 2.0-2.9 times basal values, or urine output <0.5 ml/kg/h for > _12 consecutive hours; stage 3 was a serum creatinine increase of > _4 mg/dl, or > _3 times basal values, or initiation of RRT, or urine output <0.3 ml/kg/h for > _24 consecutive hours or anuria for 12 h [8] .
The need for RRT was determined in cases of elevated azotaemia and a serial rise in serum creatinine levels; electrolyte alterations, especially severe hyperkalaemia and acid-base decompensation; persistent oliguria, refractory pulmonary oedema or fluid overload [6] . Continuous venovenous haemodiafiltration was used in all cases.
Outcomes
Preoperative data included the underlying respiratory diagnosis, comorbidities, body mass index, basal renal function, time on the waiting list and the need for preoperative extracorporeal membrane oxygenation (ECMO) as a bridge to LTX in case of terminal respiratory failure. In all cases venovenous ECMO with peripheral cannulation was started when non-corrigible hypoxic and/or hypercapnic respiratory failure developed; in some cases it was necessary to switch to venoarterial ECMO because of right heart failure or other causes of uncontrolled haemodynamics. Operative variables were unilateral/bilateral transplant, total graft ischaemia time, need for blood transfusions, significant arterial hypotension (cardiac index <2.2 l/min/m 2 and systolic arterial blood pressure <90 mmHg or the need for vasoactive medications to maintain this level of tension) and the need for intraoperative ECMO (venoarterial ECMO with central cannulation was used in patients with poorly controlled haemodynamics or low oxygenation during surgery). Postoperative variables included duration of invasive MV (if tracheostomy was performed, the interval up to the tracheostomy was considered), grade of primary graft dysfunction at 72 h (according to the 2017 definition [9] ); if any, the need for postoperative ECMO, duration of treatment with vasoactive amines and inhaled nitric oxide (NO), duration of stay in the intensive care unit (ICU), total in-hospital stay and survival at 1 year. Patients were divided according to whether or not they developed AKI and were further stratified according to the severity of the AKI.
Statistical analysis
Non-parametric statistics were applied to the data. The Mann-Whitney U-test was used to compare 2 groups; the Kruskal-Wallis test was used for 3 or more groups and Dunn's test, for multiple comparisons. Survival analysis was based on Kaplan-Meier curves. Contingency analysis was performed using the Fisher's exact test when calculating categorical data in 2-by-2 tables; in all different cases with bigger tables, the v 2 test was used. Significance was set at P < _ 0.05. All data were expressed as mean ± standard deviation. Statistical analysis was performed by StatSoft (2001) (TIBCO Software, Palo Alto, CA, USA) and GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA, USA).
RESULTS
A total of 135 patients who underwent LTX were included in this study: 69 underwent a unilateral and 66 a bilateral transplant. The underlying diseases that led to the transplant were pulmonary fibrosis (72/135 patients, 53.33% of the study population, mean age 56.2 ± 7.6 years); chronic obstructive pulmonary disease (28/135 patients, 20.74%, 57.3 ± 5.1 years); cystic fibrosis (25/ 135 patients, 18.52%, 33.4 ± 9.0 years); and other diseases (10/ 135, 7.41%, 41.9 ± 12.4 years) ( Table 1) .
Forty-five out of 135 patients (33.33%) developed AKI during the early postoperative period. They were slightly, but not significantly, older than those who did not (52.0 ± 10.8 vs 50.3 ± 12.8). Male sex was associated with an increased risk of post-transplant AKI (relative risk 1.877; P = 0.0255). No other differences in preoperative variables, such as underlying diagnosis, body mass index, smoking, basal renal function, time on waiting list and use of ECMO as a bridge to lung transplant, were observed between the 2 groups (Table 1) . Arterial hypertension and prevalence of diabetes mellitus were slightly higher in patients who developed postoperative AKI, but statistical significance was not reached (55.5% vs 38.9% and 49.9% vs 35.5%, respectively).
Uni/bilateral transplant, graft ischaemic time, intra-and postoperative blood transfusions and the need for intraoperative ECMO did not differ between patients who developed AKI and those who did not ( Table 2) . Patients who developed AKI showed a significantly higher prevalence of severe arterial hypotension with haemodynamic decompensation during surgery and in the early postoperative phase (18/45, 40% vs 14/90, 15.6%; relative risk 1.942; P = 0.006). This was also reflected by a significantly longer administration of vasoactive amines in the AKI group (122.6 ± 175.4 h vs 68.63 ± 75.22 h; P = 0.0081). Immunosuppressive therapy also played a role in the development of AKI. Induction therapy (basiliximab or thymoglobulin) and the use of tacrolimus instead of cyclosporine were protective against AKI. The use of azathioprine or mycophenolate mofetil did not differ in patients with and without AKI (see Table 2 ).
Patients with AKI had a worse respiratory outcome: they required invasive MV for a significantly longer time (62.2% of patients with AKI required more than 96 h of MV compared to 41.1% of patients without AKI; P = 0.0028), required prolonged NO inhalation (89.14 ± 90.61 vs 50.14 ± 57.46 h; P = 0.01) and showed a higher prevalence of tracheostomy (35.5% vs 17.8%; P = 0.0031) ( Table 2 ). The need for ECMO in the postoperative phase was also significantly higher in the group with AKI (15.56% vs 3.33%; P = 0.0159) ( Table 2 ). Primary graft dysfunction occurred with different degrees of severity in 30/45 (66.67%) patients in the AKI group and in 67/90 (74.44%) patients in the other group (difference not significant) ( Table 2) .
Duration of postoperative hospitalization did not differ significantly between the groups; it was 42.93 ± 31.09 days in patients with AKI and 41.03 ± 20.76 days in patients without AKI. Patients with AKI had a longer stay in the ICU (25.93 ± 21.30 vs 14.56 ± 17.29, P < 0.0001).
Statistical analyses between the different stages of AKI showed that patients with stage 3 AKI required significantly more postoperative ECMO and blood transfusions (P = 0.001 and P = 0.02, respectively). The requirement for vasoactive amines and NO inhalation was also greater but not significantly so, probably because of high data dispersion as demonstrated by the standard deviation (Table 3) . No difference in the use of immunosuppressive therapy was observed among the different AKI stages; fewer patients with AKI stage 3 received azathioprine or mycophenolate mofetil because of their poor clinical condition (Table 3) .
Patients with AKI (all stages) showed significantly lower survival rates than those who did not develop AKI (1-year survival rate, 47.1% vs 84.3%; P = 0.001) ( Fig. 1) . Patients with stage 1 and stage 2 AKI had 1-year survival rates that were substantially comparable to patients without AKI, whereas patients with grade 3 AKI (n = 25) had significantly worse survival rates (66.6%, 90% and 25%, respectively; P < _ 0.0001) (Fig. 2) . No statistically significant differences among causes of death were found between groups with and without AKI. The most frequent cause of death in both groups was infection (57.2% vs 60%), followed by graft failure (23.8% vs 6.5%), cardiovascular (4% vs 13.5%) and other causes (14.5% vs 20%) (P = 0.475).
Eighteen patients with AKI (40%) required RRT and showed worse survival rates than other patients with AKI who did not require RRT (1-year survival 15.8% vs 72%; P < 0.0001). 
DISCUSSION
AKI is a frequent postoperative complication and is a very negative prognostic condition that can significantly affect the outcome of patients who underwent LTX [3] . Arterial hypotension, low cardiac output and severe bleeding have been proposed as major risk factors for postoperative AKI [4] . We retrospectively evaluated the data from a population of patients undergoing LTX in a single institution to assess the incidence and impact of postoperative AKI on transplant outcome. Our study confirmed that AKI is a frequent complication of LTX (33% of our patients); however, our findings are in line with those of previous studies that reported even higher rates of AKI (45-60%) [9, 10] . Altered renal function prior to lung transplant was previously associated with the development of renal dysfunction [4] . Our protocol is particularly strict on this question: we do not usually list patients with impaired renal function; none of patients included in the study showed preoperative creatinine clearance <50 ml/min. This result could partly explain our low incidence of AKI. No pretransplant conditions or factors proved to be associated with the onset of AKI in our population. Prevalence of comorbidity commonly associated with kidney dysfunction, such as arterial hypertension and diabetes mellitus, was not statistically higher in patients who developed AKI as well as the need for ECMO as a bridge to transplantation. The only statistically significant difference between patients who developed AKI and those who did not was gender distribution: AKI was more common in male patients. This result is difficult to explain and is probably related to statistical power because of our relatively small population. However, data from the International Society for Heart and Lung Transplantation registry shows that men have significantly worse lung transplant outcomes than women [7] .
Haemodynamics proved to have the greatest impact on the development of AKI, confirming previous observations [4] . Patients who developed AKI showed marginal and poorly controlled haemodynamics during surgery and in the early postoperative phase, with significant hypotension and the need for greater vasoactive amine support. Such therapies were even more important in patients with severe AKI who needed RRT. The duration and type of surgery (unilateral or bilateral transplant, duration of ischaemia, bleeding rates) of our patients did not prove to be associated with the development of AKI.
AKI was associated with negative respiratory function and patient outcomes. Patients who developed AKI were sicker, required longer invasive MV and NO inhalation therapy, and showed a higher prevalence of tracheostomy and of the need for postoperative ECMO. Postoperative AKI proved to be negatively associated with survival [3, 5, 6] . In our cohort, we confirmed a significantly poorer 1-year survival rate of patients with AKI, particularly those with grade 3 AKI who needed RRT and who showed poorer outcomes and survival rates. Moreover, patients with grade 3 AKI required postoperative ECMO and blood transfusion more frequently, and, due to their poor clinical condition, the introduction of azathioprine or mycophenolate was delayed or avoided. Patients with grades 1 and 2 AKI did not show significantly different survival rates compared to patients with spared renal function.
Moreover, we analysed the incidence of AKI over time at our centre and found a significant decrease in recent years In 2009 we modified our protocol by introducing basiliximab and reducing the calcineurin inhibitor trough levels; these changes might have contributed to the reduction in the prevalence of AKI. High blood levels of tacrolimus have been proposed as a risk factor for AKI [5, 11] ; nevertheless, in our study the use of tacrolimus instead of cyclosporine was not closely associated with AKI.
AKI after LTX has been associated with increased reliance on health care resources after surgery and discharge [12] . In our cohort, time spent in intensive care was significantly longer for patients who developed AKI, though patients with severe renal impairment (stage 3) had shorter stays in the ICU due to poor survival rates.
Limitations
The major limits of this study are its retrospective and monocentric nature, the long period of observation during which some changes in population and immunosuppressive protocol occurred, and the fact that it is based on a relatively small population with consequently a low event rate for AKI. No patients with pulmonary arterial hypertension, who are more likely to benefit from RRT after LTX, were included in the study [13] . Other prospective studies on large populations are needed to better identify factors associated with the onset of AKI and successful preventive strategies.
CONCLUSION
In conclusion, our results confirm the importance of renal function in the early postoperative phase after LTX and underline the need for a precise intra-and postoperative therapeutic approach to reduce the frequency and severity of AKI. The pathogenesis of AKI is heterogeneous, and prerenal causes have a great impact. Particular attention must be paid to the haemodynamics, which proved to be strongly associated with the onset of AKI. Correct fluid and vasoactive therapy during and after the operation are keys for successful haemodynamic management and renal protection. Severe AKI proved to have an absolutely negative impact on patients who underwent LTX and was associated with respiratory impairment, longer stay in the ICU, recourse to expensive therapies such as RRT and reduced survival rates.
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